Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This phase I clinical trial is studying the side effects and best dose of azacitidine when given together with mitoxantrone, etoposide phosphate, and cytarabine in treating patients with relapsed or refractory acute myeloid leukemia. Azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as mitoxantrone, etoposide phosphate, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Azacitidine may help mitoxantrone, etoposide phosphate, and cytarabine work better by making cancer cells more sensitive to the drugs.
| Condition | Intervention | Phase |
|---|---|---|
|
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Recurrent Adult Acute Myeloid Leukemia |
Drug: azacitidine Drug: mitoxantrone hydrochloride Drug: etoposide Drug: cytarabine Other: laboratory biomarker analysis Other: pharmacological study |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase 1 Study of Azacitidine in Combination With MEC (Mitoxantrone, Etoposide, Cytarabine) in Relapsed and Refractory Acute Myeloid Leukemia. |
- Maximum-tolerated dose of azacitidine when combined with salvage chemotherapy (mitoxantrone hydrochloride, etoposide, and cytarabine [MEC]) via National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 [ Time Frame: By day 42 ] [ Designated as safety issue: Yes ]Frequency distributions and other descriptive measures will form the basis of the analysis of these variables
- Qualitative and quantitative toxicities of azacitidine in combination with MEC graded via NCI CTCAE v4.0 [ Time Frame: Up to 30 days post-therapy ] [ Designated as safety issue: Yes ]
- Clinical response according to the International Working Group criteria [ Time Frame: Day 42 ] [ Designated as safety issue: No ]Responses will be summarized by simple descriptive summary statistics delineating complete and lesser responses as well as stable and progressive disease.
| Estimated Enrollment: | 24 |
| Study Start Date: | January 2011 |
| Estimated Primary Completion Date: | July 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Treatment (azacitidine, mitoxantrone, etoposide, cytarabine)
Patients receive azacitidine IV over 30 minutes on days 1-8 and mitoxantrone hydrochloride IV over 10 minutes, etoposide phosphate IV over 30-60 minutes, and cytarabine IV over 6 hours on days 3-8 in the absence of disease progression or unacceptable toxicity. Treatment may repeat every 8 days for 1 additional course. Blood and bone marrow samples are collected at baseline and periodically during study for pharmacokinetic and pharmacodynamic studies.
|
Drug: azacitidine
Given IV
Other Names:
Drug: mitoxantrone hydrochloride
Given IV
Other Names:
Drug: etoposide
Given IV
Other Names:
Drug: cytarabine
Given IV
Other Names:
Other: laboratory biomarker analysis
Correlative studies
Other: pharmacological study
Correlative studies
Other Name: pharmacological studies
|
Detailed Description:
PRIMARY OBJECTIVES:
I. To determine the maximum-tolerated dose of azacitidine when combined with salvage chemotherapy comprising mitoxantrone hydrochloride, etoposide phosphate, and cytarabine (MEC) in patients with relapsed or refractory acute myeloid leukemia (AML).
SECONDARY OBJECTIVES:
I. To define the qualitative and quantitative toxicities of azacitidine in combination with MEC with regard to organ specificity, time course, predictability, and reversibility.
II. To document the rate of complete remission (CR) and CR with incomplete blood count recovery (CRi) in patients treated with this combination of agents.
III. To determine the overall survival, relapse-free survival, and event-free survival of patients treated with this combination of agents.
IV. To evaluate the pharmacokinetics of azacitidine when given in combination with MEC in patients enrolled on this study. (Exploratory) V. To measure R2 down regulation, including changes in R2 target, AraCTP, and dNTP/NTP pools, of azacitidine when given in combination with MEC and to correlate these pharmacodynamic endpoints with clinical response. (Exploratory) VI. To evaluate hypomethylation, including DMNT1 expression, Sp1 expression, global DNA methylation, gene expression profiling, and microRNA expression profiling, of azacitidine when given in combination with MEC and to correlate these pharmacodynamic changes with clinical response. (Exploratory)
OUTLINE: This is a dose-escalation study of azacitidine.
Patients receive azacitidine IV over 30 minutes on days 1-8 and mitoxantrone hydrochloride IV over 10 minutes, etoposide phosphate IV over 30-60 minutes, and cytarabine IV over 6 hours on days 3-8 in the absence of disease progression or unacceptable toxicity. Treatment may repeat every 8 days for 1 additional course. Blood and bone marrow samples are collected at baseline and periodically during study for pharmacokinetic and pharmacodynamic studies.
After completion of study therapy, patients are followed up for 30 days.
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Histologically or cytologically confirmed acute myeloid leukemia
- Relapsed or refractory disease according to 2008 WHO classification
- Must have failed ≥ 1 course of induction chemotherapy or relapsed after achieving a complete remission after induction therapy
- No active central nervous system disease or granulocytic sarcoma as sole site of disease
- ECOG performance status (PS) 0-2 (Karnofsky PS 60-100%)
- Life expectancy > 6 months for any comorbid conditions
- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
- AST and ALT ≤ 2.5 times ULN
- Creatinine ≤ 1.5 mg/dL
- LVEF ≥ 40%
- Not pregnant or nursing
- Negative pregnancy test
- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to azacitidine, mannitol, or other agents used in the study
No uncontrolled intercurrent illness including, but not limited to, any of the following:
- Symptomatic congestive heart failure
- Unstable angina pectoris
- Serious cardiac arrhythmia
- Psychiatric illness and/or social situations that would limit compliance with study requirements
None of the following:
- Myocardial infarction within the past 6 months
- NYHA class III or IV heart failure
- Uncontrolled angina
- Severe uncontrolled ventricular arrhythmias
- Electrocardiographic evidence of acute ischemia or active conduction system abnormalities
- Patients with active infection allowed provided the infection is controlled
- No other concurrent anticancer agents or therapies, including chemotherapy, radiotherapy (including palliative), or biologic response modifiers
- Prior autologous or allogeneic stem cell transplantation allowed
- Recovered from non-hematologic toxicity to < grade 2
- More than 2 weeks since prior chemotherapy or radiotherapy (6 weeks for nitrosoureas or mitomycin C)
- More than 14 days since prior and no other concurrent investigational agents
- No concurrent combination antiretroviral therapy for HIV-positive patients
Contacts and Locations| United States, Ohio | |
| Ohio State University Medical Center | Recruiting |
| Columbus, Ohio, United States, 43210 | |
| Contact: Rebecca B. Klisovic 614-366-3802 rebecca.klisovic@osumc.edu | |
| Principal Investigator: Rebecca B. Klisovic | |
| Principal Investigator: | Rebecca Klisovic | Ohio State University |
More Information
No publications provided
| Responsible Party: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT01249430 History of Changes |
| Other Study ID Numbers: | NCI-2011-02554, OSU 10093, CDR0000689575, OSU-10093, U01CA076576 |
| Study First Received: | November 25, 2010 |
| Last Updated: | March 26, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Congenital Abnormalities Leukemia Leukemia, Myeloid, Acute Leukemia, Myeloid Neoplasms by Histologic Type Neoplasms Azacitidine Cytarabine Etoposide phosphate Etoposide Mitoxantrone Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action |
Pharmacologic Actions Antineoplastic Agents Therapeutic Uses Enzyme Inhibitors Antiviral Agents Anti-Infective Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents, Phytogenic Analgesics Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents |
ClinicalTrials.gov processed this record on May 16, 2013